Claims for Patent: 12,559,474

Summary for Patent: 12,559,474

Title:	Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same
Abstract:	A compound represented by Formula (I): wherein Y is N or the like; R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is substituted or unsubstituted aromatic carbocyclyl or the like; R3 is substituted or unsubstituted aromatic heterocyclyl or the like; —X— is —NH— or the like; m is 1 or the like; R5a is each independently a hydrogen atom or the like; R5b is each independently a hydrogen atom or the like; n is 1 or the like; R4a is each independently a hydrogen atom or the like; and R4b is each independently a hydrogen atom or the like, or a pharmaceutically acceptable salt thereof.
Inventor(s):	Yuki Tachibana, Shota UEHARA, Yuto Unoh, Kenji Nakahara, Yoshiyuki Taoda, Koji KASAMATSU, Yukiko YAMATSU, Shigeru Ando, Takahiro SUTO, Michihito SASAKI
Assignee:	Hokkaido University NUC , Shionogi and Co Ltd
Application Number:	US17/790,358
Patent Claims:	1. A compound represented by Formula (I): wherein Y is N, or CR7; R7 is a hydrogen atom, or substituted or unsubstituted alkyl; R1 is substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted non-aromatic heterocyclyl, or substituted or unsubstituted carbamoyl; R2 is 6 membered aromatic carbocyclyl substituted with one halogen or one cyano, and further substituted with 1, 2, 3 or 4 substituent(s) selected from substituent group G, or 6 membered aromatic heterocyclyl substituted with one halogen or one cyano, and further substituted with 1 or 2 substituent(s) selected from substituent group G; substituent group G is selected from the group consisting of halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkyloxy, alkenyloxy, alkynyloxy and haloalkyloxy; R3 is substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted non-aromatic heterocyclyl, or substituted or unsubstituted alkyl; —X— is —NR6—, —CR6R6′—, —O—, —S—, or a single bond; R6 and R6′ are each independently a hydrogen atom, or substituted or unsubstituted alkyl; m is 0, 1, or 2; R5a is each independently a hydrogen atom, or substituted or unsubstituted alkyl; R5b is each independently a hydrogen atom, or substituted or unsubstituted alkyl; n is 1; R4a is each independently a hydrogen atom, or substituted or unsubstituted alkyl; and R4b is each independently a hydrogen atom, or substituted or unsubstituted alkyl, or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1, wherein Y is N, or a pharmaceutically acceptable salt thereof. 3. The compound according to claim 1, wherein —X— is —NH—, or a pharmaceutically acceptable salt thereof. 4. The compound according to claim 1, wherein m is 0 or 1, or a pharmaceutically acceptable salt thereof. 5. The compound according to claim 1, wherein R4a is each independently a hydrogen atom or unsubstituted alkyl, and R4b is each independently a hydrogen atom, or a pharmaceutically acceptable salt thereof. 6. The compound according to claim 1, wherein R5a is each independently a hydrogen atom, and R5b is each independently a hydrogen atom, or a pharmaceutically acceptable salt thereof. 7. The compound according to claim 1, wherein R1 is substituted or unsubstituted aromatic heterocyclyl, or a pharmaceutically acceptable salt thereof. 8. The compound according to claim 1, wherein R1 is substituted or unsubstituted aromatic heterocyclyl, m is 1, R5a is a hydrogen atom, and R5b is a hydrogen atom, or pharmaceutically acceptable salt thereof. 9. The compound according to claim 1, wherein R1 is substituted or unsubstituted aromatic heterocyclyl, and m is 0, or a pharmaceutically acceptable salt thereof. 10. The compound according to claim 1, wherein R3 is substituted or unsubstituted 6 membered aromatic carbocyclyl, substituted or unsubstituted 3 to 10 membered non-aromatic carbocyclyl, substituted or unsubstituted 5 to 6 membered aromatic heterocyclyl, substituted or unsubstituted 9 to 10 membered aromatic heterocyclyl, substituted or unsubstituted 13 to 15 membered aromatic heterocyclyl, or substituted or unsubstituted 3 to 20 membered non-aromatic heterocyclyl, or a pharmaceutically acceptable salt thereof. 11. The compound according to claim 1, wherein R3 is substituted or unsubstituted 6 membered aromatic carbocyclyl, substituted or unsubstituted 9 to 10 membered aromatic heterocyclyl, or substituted or unsubstituted 9 to 13 membered non-aromatic heterocyclyl, or a pharmaceutically acceptable salt thereof. 12. The compound according to claim 1, wherein Formula (I) is Formula (I′): wherein R1′ is a group represented by Formula: R2′ is a group represented by Formula: and R3′ is a group represented by Formula: or a pharmaceutically acceptable salt thereof. 13. The compound according to claim 1, wherein Formula (I) is Formula (I′): wherein R1′ is a group represented by Formula: R2′ is a group represented by Formula: and R3′ is a group represented by Formula: or a pharmaceutically acceptable salt thereof. 14. The compound according to claim 1, wherein the compound is selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 15. A pharmaceutical composition comprising the compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive, carrier or diluent. 16. A method for inhibiting SARS-COV-2, comprising administering the compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a subject. 17. A method for treating an infection caused by SARS-COV-2, comprising administering the compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a subject.